The trajectory of companies tied to the drug's past presents a intricate investment landscape. While the initial surge generated substantial profits , generic alternatives have significantly impacted sales . Investing in related pharmaceutical businesses now requires a careful assessment of intellectual property protection , evolving healthcare cha